Home LiteratureArticle Details
PMID: 18812504 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG

Abstract

Lung disease is the leading cause of morbidity and mortality in cystic fibrosis (CF) patients. A modest number of bacterial pathogens have been correlated with pulmonary function decline; however, microbiological and molecular evidence suggests that CF airway infection is polymicrobial. To obtain a more complete assessment of the microbial community composition and dynamics, we undertook a longitudinal study by using culture-independent and microbiological approaches. In the process, we demonstrated that within complex and dynamic communities, the Streptococcus milleri group (SMG) can establish chronic pulmonary infections and at the onset of 39% of acute pulmonary exacerbations, SMG is the numerically dominant pathogen. We report the comprehensive polymicrobial community dynamics of a CF lung infection in a clinically relevant context. If a given organism, such as Pseudomonas aeruginosa, becomes resistant to antibiotic therapy, an alternative treatment avenue may mediate the desired clinical response by effectively managing the composition of the microbial community.

MeSH Terms
Adult Bacterial Infections/microbiology Cystic Fibrosis/microbiology Drug Resistance, Bacterial Female Humans Longitudinal Studies Lung/microbiology Male Middle Aged Polymorphism, Restriction Fragment Length Pseudomonas aeruginosa/drug effects,genetics,isolation & purification Sputum/microbiology Streptococcus constellatus/drug effects,genetics,isolation & purification
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Sibley Christopher D
Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, AB, Canada T2N 4N1.
Parkins Michael D
Rabin Harvey R
Duan Kangmin
Norgaard Jens C
Surette Michael G
References (56)
56 references, click to expand
  1. Degradation and utilisation of chondroitin sulphate by Streptococcus intermedius.
    J Med Microbiol. 1996 May;44(5):372-80 PMID: 8636952
  2. The importance of recognising Streptococcus milleri as a cause of orbital cellulitis.
    Eye (Lond). 2000 Oct;14 Pt 5:814-5 PMID: 11116727
  3. Cluster analysis and display of genome-wide expression patterns.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 PMID: 9843981
  4. Streptococci and aerococci associated with systemic infection in man.
    J Med Microbiol. 1976 Aug;9(3):275-302 PMID: 785000
  5. Association between Streptococcus milleri and abscess formation after appendicitis.
    Ann R Coll Surg Engl. 2000 Jan;82(1):24-6 PMID: 10700762
  6. The Streptococcus milleri group--an unrecognized cause of disease in cystic fibrosis: a case series and literature review.
    Pediatr Pulmonol. 2008 May;43(5):490-7 PMID: 18383109
  7. Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms.
    Thorax. 1989 Sep;44(9):739-42 PMID: 2588211
  8. Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections.
    J Clin Microbiol. 1992 Jan;30(1):243-4 PMID: 1734062
  9. Trends in antimicrobial susceptibility of the Streptococcus milleri group.
    J Infect Chemother. 2002 Jun;8(2):134-7 PMID: 12111565
  10. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
    Proc Natl Acad Sci U S A. 2006 May 30;103(22):8487-92 PMID: 16687478
  11. Pulmonary infections in patients with cystic fibrosis.
    Semin Respir Infect. 2002 Mar;17(1):47-56 PMID: 11891518
  12. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
    Am J Respir Crit Care Med. 2008 May 1;177(9):995-1001 PMID: 18263800
  13. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.
    Cell. 1996 Apr 19;85(2):229-36 PMID: 8612275
  14. Antimicrobial susceptibilities of species of viridans streptococci.
    J Infect Dis. 1979 Sep;140(3):316-21 PMID: 501146
  15. Acute bronchopulmonary infection due to Streptococcus milleri in a child with cystic fibrosis.
    Arch Dis Child. 1999 Mar;80(3):278-9 PMID: 10325713
  16. Clinical significance of Streptococcus milleri.
    Eur J Clin Microbiol. 1985 Aug;4(4):386-90 PMID: 4043055
  17. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.
    J Clin Microbiol. 2006 Jul;44(7):2601-4 PMID: 16825392
  18. Reliability for detecting composition and changes of microbial communities by T-RFLP genetic profiling.
    FEMS Microbiol Ecol. 2008 Feb;63(2):249-60 PMID: 18177353
  19. The cultural and biochemical characters of Streptococcus milleri strains isolated from human sources.
    J Hyg (Lond). 1979 Feb;82(1):63-78 PMID: 762404
  20. Hydrolytic enzymes of Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius in relation to infection.
    Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):818-20 PMID: 8536735
  21. Bacterial activity in cystic fibrosis lung infections.
    Respir Res. 2005;6:49 PMID: 15929792
  22. Hyaluronidase production in Streptococcus milleri in relation to infection.
    J Clin Pathol. 1989 May;42(5):506-10 PMID: 2732345
  23. Occurrence and cultural features of Streptococcus milleri in various body sites.
    J Clin Pathol. 1979 Aug;32(8):764-8 PMID: 512036
  24. Clinical and bacterial features of infections caused by Streptococcus milleri.
    Scand J Infect Dis. 1991;23(6):659-66 PMID: 1815325
  25. U.K. Controlled trial of intrapleural streptokinase for pleural infection.
    N Engl J Med. 2005 Mar 3;352(9):865-74 PMID: 15745977
  26. Streptococcus milleri group: renewed interest in an elusive pathogen.
    Eur J Clin Microbiol Infect Dis. 1992 Jun;11(6):491-8 PMID: 1526231
  27. Effects of acute viral respiratory tract infections in patients with cystic fibrosis.
    Pediatr Pulmonol. 1989;7(4):217-22 PMID: 2616245
  28. Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen.
    Clin Microbiol Rev. 1988 Jan;1(1):102-8 PMID: 3060239
  29. STUDIES ON A NON-HEMOLYTIC STREPTOCOCCUS ISOLATED FROM THE RESPIRATORY TRACT OF HUMAN BEINGS : I. BIOLOGICAL CHARACTERISTICS OF STREPTOCOCCUS MG.
    J Exp Med. 1944 Nov 1;80(5):391-406 PMID: 19871426
  30. Streptococcus milleri-sepsis with lung and brain abscesses.
    Acta Clin Belg. 2004 Nov-Dec;59(6):369-72 PMID: 15819383
  31. Production of deoxyribonuclease, ribonuclease, coagulase, and hemolysins by anaerobic gram-positive cocci.
    J Clin Microbiol. 1981 Apr;13(4):787-8 PMID: 7229018
  32. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA.
    Appl Environ Microbiol. 1997 Nov;63(11):4516-22 PMID: 9361437
  33. Streptococcus milleri: an organism for head and neck infections and abscess.
    Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):650-4 PMID: 11405863
  34. Thoracic infection caused by Streptococcus milleri.
    Eur Respir J. 1998 Aug;12(2):357-62 PMID: 9727785
  35. Liver abscess caused by Streptococcus milleri.
    Rev Infect Dis. 1989 Mar-Apr;11(2):197-202 PMID: 2649957
  36. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.
    Cell. 1998 Dec 23;95(7):1005-15 PMID: 9875854
  37. Bacteremia involving the "Streptococcus milleri" group: analysis of 19 cases.
    Clin Infect Dis. 1994 Oct;19(4):704-13 PMID: 7803636
  38. characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling.
    J Clin Microbiol. 2004 Nov;42(11):5176-83 PMID: 15528712
  39. Genotypic and phenotypic characterization of "Streptococcus milleri" group isolates from a Veterans Administration hospital population.
    J Clin Microbiol. 1999 Nov;37(11):3681-7 PMID: 10523574
  40. Clinically significant infections with organisms of the Streptococcus milleri group.
    Pediatr Infect Dis J. 2002 Aug;21(8):715-23 PMID: 12192158
  41. Biochemical properties of CO2-dependent streptococci.
    J Clin Microbiol. 1980 Jul;12(1):27-31 PMID: 6775006
  42. Streptococcus milleri group (Streptococcus anginosus): recovery from intra-abdominal and soft tissue sites.
    Ann Clin Lab Sci. 1991 Jan-Feb;21(1):56-61 PMID: 2012380
  43. Occurrence and pathogenicity of the Streptococcus milleri group.
    Rev Infect Dis. 1988 Mar-Apr;10(2):257-85 PMID: 3287560
  44. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.
    J Clin Microbiol. 2003 Aug;41(8):3548-58 PMID: 12904354
  45. Lung infections associated with cystic fibrosis.
    Clin Microbiol Rev. 2002 Apr;15(2):194-222 PMID: 11932230
  46. Web-based phylogenetic assignment tool for analysis of terminal restriction fragment length polymorphism profiles of microbial communities.
    Appl Environ Microbiol. 2003 Nov;69(11):6768-76 PMID: 14602639
  47. Seven-year review of bacteremia caused by Streptococcus milleri and other viridans streptococci.
    Eur J Clin Microbiol Infect Dis. 1996 May;15(5):365-71 PMID: 8793393
  48. Hydrolytic enzymes of anaerobic bacteria isolated from human infections.
    J Clin Microbiol. 1981 Aug;14(2):153-6 PMID: 6268657
  49. Cystic fibrosis: a polymicrobial infectious disease.
    Future Microbiol. 2006 Jun;1(1):53-61 PMID: 17661685
  50. Phenotypic differentiation of Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus strains within the "Streptococcus milleri group".
    J Clin Microbiol. 1990 Jul;28(7):1497-501 PMID: 2380375
  51. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication.
    Mol Microbiol. 2003 Dec;50(5):1477-91 PMID: 14651632
  52. Macrorestriction fingerprinting of "Streptococcus milleri" group bacteria by pulsed-field gel electrophoresis.
    J Clin Microbiol. 2000 Jun;38(6):2141-9 PMID: 10834967
  53. The Streptococcus milleri group as a cause of pulmonary infections.
    Clin Infect Dis. 1995 Dec;21 Suppl 3:S238-43 PMID: 8749672
  54. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis.
    Cell. 1997 Feb 21;88(4):553-60 PMID: 9038346
  55. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20529-33 PMID: 18077362
  56. Serious infections caused by Streptococcus milleri.
    Am J Med. 1978 May;64(5):759-64 PMID: 645741
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2008-09-30
Epub
2008-00-23
Pages
15070-5
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC2567494
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com